GlassScriptPhysician profile
Cindy S Jacob
NPI 1174747661
$10,158.58
in general payments reported to CMS, 2019-2025
53 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,484 · 2020: $1,116 · 2021: $1,616 · 2022: $1,343 · 2023: $2,026 · 2024: $1,290 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,514 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,514.24 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,449.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,238.47 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,163.74 | 2019-2025 | |
| Pfizer INC. | $694.88 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $690.76 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Amgen INC. | $503.42 | 2019-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $485.80 | 2019-2023 | |
| Glaxosmithkline, LLC. | $453.55 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $324.77 | 2019-2025 | Mounjaro, Omvoh, Emgality |
| Otsuka America Pharmaceutical, INC. | $290.95 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.98 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Madrigal Pharmaceuticals | $225.50 | 2024-2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $224.01 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $174.65 | 2019-2023 | Belsomra, Steglatro, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $173.77 | 2019-2025 | Eohilia, Entyvio |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.